<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00543803</url>
  </required_header>
  <id_info>
    <org_study_id>1100.1492</org_study_id>
    <nct_id>NCT00543803</nct_id>
  </id_info>
  <brief_title>Observational Non-interventional Study With Viramune® in Combination With Truvada® in HIV-infected Patients</brief_title>
  <official_title>Observational Non-interventional Study Evaluating the Safety and Efficacy of Truvada + Nevirapine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      This observational study is supposed to assess (under conditions of clinical practice in
      daily routine) whether treatment with Viramune (nevirapine) in combination with Truvada
      (tenofovir and emtricitabine) will durably suppress viral load below the limit of detection
      or will maintain suppression of viral replication (HIV-RNA below limit of detection) achieved
      under previous anti-retroviral combination therapy after switch to combination treatment of
      Viramune (nevirapine) and Truvada (tenofovir and emtricitabine).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Summary of Change From Baseline in Alanine Aminotransferase (ALT) to Last Value on Treatment</measure>
    <time_frame>from baseline to last value on treatment in between 36 months</time_frame>
    <description>The change in alanine aminotransferase (ALT) from baseline to the last value in treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Summary of Change From Baseline in Asparate Aminotransferase (AST) to Last Value on Treatment</measure>
    <time_frame>from baseline to last value on treatment in between 36 months</time_frame>
    <description>The change in asparate aminotransferase (AST) from baseline to the last value in treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Summary of Change From Baseline in Gamma-glutamyl Transferase (Gamma-GT) to Last Value on Treatment</measure>
    <time_frame>from baseline to last value on treatment in between 36 months</time_frame>
    <description>The change in Gamma-glutamyl transferase (Gamma-GT) from baseline to the last value in treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Summary of Change From Baseline in Creatinine to Last Value on Treatment</measure>
    <time_frame>from baseline to last value on treatment in between 36 months</time_frame>
    <description>The change in Creatinine from baseline to the last value in treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Summary of Change From Baseline in Total Cholesterol to Last Value on Treatment</measure>
    <time_frame>from baseline to last value on treatment in between 36 months</time_frame>
    <description>The change in total cholesterol from baseline to the last value in treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Summary of Change From Baseline in High-density Lipoprotein (HDL) Cholesterol to Last Value on Treatment</measure>
    <time_frame>from baseline to last value on treatment in between 36 months</time_frame>
    <description>The change in High-density lipoprotein (HDL) cholesterol from baseline to the last value in treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Summary of Change From Baseline in Low-density Lipoprotein (LDL) Cholesterol to Last Value on Treatment</measure>
    <time_frame>from baseline to last value on treatment in between 36 months</time_frame>
    <description>The change in Low-density lipoprotein (LDL) cholesterol from baseline to the last value in treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Summary of Change From Baseline in Triglycerides to Last Value on Treatment</measure>
    <time_frame>from baseline to last value on treatment in between 36 months</time_frame>
    <description>The change in triglycerides from baseline to the last value in treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Summary of Change From Baseline in Glucose to Last Value on Treatment</measure>
    <time_frame>from baseline to last value on treatment in between 36 months</time_frame>
    <description>The change in Glucose from baseline to the last value in treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Summary of Log10 Change From Baseline in Viral Load to Last Value on Treatment</measure>
    <time_frame>from baseline to last value on treatment in between 36 months</time_frame>
    <description>For calculation of this measure switch patients are included in the total which had no viral load decrease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Change From Baseline in CD4+ Count to Last Value on Treatment</measure>
    <time_frame>from baseline to last value on treatment in between 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Non-serious Drug-related AEs as Judged by the Investigator</measure>
    <time_frame>from baseline to last value on treatment in between 36 months</time_frame>
    <description>Total number of patients with investigator defined non-serious drug-related AEs was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator's Global Clinical Assessment of Patient General Health Status</measure>
    <time_frame>from baseline to last value on treatment in between 36 months</time_frame>
    <description>Investigators opinion of patients general health condition at baseline versus last evaluation on treatment</description>
  </secondary_outcome>
  <enrollment type="Actual">334</enrollment>
  <condition>HIV Infections</condition>
  <eligibility>
    <study_pop>
      <textblock>
        HIV Patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria

          -  male and female adult HIV type 1 infected patients, who have either not been treated
             previously, whose previous combination treatment with PIs has failed, or who have to
             switch their previous treatment from protease inhibitors (PI) or non-nucleoside
             reverse transcriptase inhibitors (NNRT)I due to side effects or intolerability after
             achieving suppression of viral load below the limit of detection.

          -  Viramune (nevirapine) is indicated as part of combination therapy for the antiviral
             treatment of HIV-1 infected patients with advanced or progressive immunodeficiency.

          -  Truvada (tenofovir and emtricitabine) is indicated in antiretroviral combination
             therapy for the treatment of HIV-1 infected adults.

        Exclusion criteria

          -  Age &lt; 18 years

          -  Pregnant female patients

          -  Hypersensitivity to the active substance or to any of the excipients of Viramune
             (nevirapine) or Truvada (tenofovir and emtricitabine).

          -  Viramune (nevirapine) should not be readministered to patients who have required
             permanent discontinuation for severe rash, rash accompanied by constitutional
             symptoms, hypersensitivity reactions, or clinical hepatitis due to nevirapine.

          -  Viramune (nevirapine) should not be used in patients with severe hepatic impairment
             (Child-Pugh C) or pre-treatment aspartine transaminase (ASAT) or alanine transaminase
             (ALAT) &gt; 5 upper limit normal (ULN) until baseline ASAT/ALAT are stabilised &lt; 5 ULN.

          -  Viramune (nevirapine) should not be readministered in patients who previously had ASAT
             or ALAT &gt; 5 ULN during Viramune (nevirapine) therapy and had recurrence of liver
             function abnormalities upon readministration of Viramune (nevirapine)

          -  Herbal preparations containing St Johns wort (Hypericum perforatum) must not be used
             while taking Viramune (nevirapine) due to the risk of decreased plasma concentrations
             and reduced clinical effects of nevirapine

          -  The available pharmacokinetic data suggest that the concomitant use of rifampicin and
             Viramune (nevirapine) is not recommended.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1492.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 10</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 11</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 12</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 13</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 14</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 1</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 2</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 3</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 4</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 5</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 6</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 7</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 8</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 9</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dortmund</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Duisburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 1</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 2</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 1</name>
      <address>
        <city>Frankfurt/Main</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 2</name>
      <address>
        <city>Frankfurt/Main</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 3</name>
      <address>
        <city>Frankfurt/Main</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 4</name>
      <address>
        <city>Frankfurt/Main</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Frankfurt/Oder</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 1</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 2</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 3</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 4</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 1</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 2</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Karlsruhe</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Koblenz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 1</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 2</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 3</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 1</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 2</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 1</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 2</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 3</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 4</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 5</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 1</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 2</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 3</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 4</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 1</name>
      <address>
        <city>Nürnberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 2</name>
      <address>
        <city>Nürnberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oldenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osnabrueck</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Potsdam</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saarbruecken</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 1</name>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 2</name>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 3</name>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Troisdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wiesbaden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wuppertal</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2007</study_first_submitted>
  <study_first_submitted_qc>October 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2007</study_first_posted>
  <results_first_submitted>December 17, 2010</results_first_submitted>
  <results_first_submitted_qc>December 17, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 13, 2011</results_first_posted>
  <last_update_submitted>May 13, 2014</last_update_submitted>
  <last_update_submitted_qc>May 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2014</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Patients Treated With Viramune in Combination With Truvada</title>
          <description>Viramune one tablet 200 mg qd for two weeks, then 200 mg bid, Truvada one tablet qd</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="334"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="192"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="142"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>not specified</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>FAS - All patients were considered for the full analysis set.</population>
      <group_list>
        <group group_id="B1">
          <title>Patients Treated With Viramune in Combination With Truvada</title>
          <description>Viramune one tablet 200 mg qd for two weeks, then 200 mg bid, Truvada one tablet qd</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="334"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.8" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Summary of Change From Baseline in Alanine Aminotransferase (ALT) to Last Value on Treatment</title>
        <description>The change in alanine aminotransferase (ALT) from baseline to the last value in treatment</description>
        <time_frame>from baseline to last value on treatment in between 36 months</time_frame>
        <population>FAS- All patients were considered for the full analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients Treated With Viramune in Combination With Truvada</title>
            <description>Viramune one tablet 200 mg qd for two weeks, then 200 mg bid, Truvada one tablet qd</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Change From Baseline in Alanine Aminotransferase (ALT) to Last Value on Treatment</title>
          <description>The change in alanine aminotransferase (ALT) from baseline to the last value in treatment</description>
          <population>FAS- All patients were considered for the full analysis set.</population>
          <units>IU/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="-3.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Summary of Change From Baseline in Asparate Aminotransferase (AST) to Last Value on Treatment</title>
        <description>The change in asparate aminotransferase (AST) from baseline to the last value in treatment</description>
        <time_frame>from baseline to last value on treatment in between 36 months</time_frame>
        <population>FAS- All patients were considered for the full analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients Treated With Viramune in Combination With Truvada</title>
            <description>Viramune one tablet 200 mg qd for two weeks, then 200 mg bid, Truvada one tablet qd</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Change From Baseline in Asparate Aminotransferase (AST) to Last Value on Treatment</title>
          <description>The change in asparate aminotransferase (AST) from baseline to the last value in treatment</description>
          <population>FAS- All patients were considered for the full analysis set.</population>
          <units>IU/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="317"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="-4.0" upper_limit="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Summary of Change From Baseline in Gamma-glutamyl Transferase (Gamma-GT) to Last Value on Treatment</title>
        <description>The change in Gamma-glutamyl transferase (Gamma-GT) from baseline to the last value in treatment</description>
        <time_frame>from baseline to last value on treatment in between 36 months</time_frame>
        <population>FAS- All patients were considered for the full analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients Treated With Viramune in Combination With Truvada</title>
            <description>Viramune one tablet 200 mg qd for two weeks, then 200 mg bid, Truvada one tablet qd</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Change From Baseline in Gamma-glutamyl Transferase (Gamma-GT) to Last Value on Treatment</title>
          <description>The change in Gamma-glutamyl transferase (Gamma-GT) from baseline to the last value in treatment</description>
          <population>FAS- All patients were considered for the full analysis set.</population>
          <units>IU/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="315"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.0" lower_limit="9.0" upper_limit="59.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Summary of Change From Baseline in Creatinine to Last Value on Treatment</title>
        <description>The change in Creatinine from baseline to the last value in treatment</description>
        <time_frame>from baseline to last value on treatment in between 36 months</time_frame>
        <population>FAS- All patients were considered for the full analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients Treated With Viramune in Combination With Truvada</title>
            <description>Viramune one tablet 200 mg qd for two weeks, then 200 mg bid, Truvada one tablet qd</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Change From Baseline in Creatinine to Last Value on Treatment</title>
          <description>The change in Creatinine from baseline to the last value in treatment</description>
          <population>FAS- All patients were considered for the full analysis set.</population>
          <units>mg/dl</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-0.1" upper_limit="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Summary of Change From Baseline in Total Cholesterol to Last Value on Treatment</title>
        <description>The change in total cholesterol from baseline to the last value in treatment</description>
        <time_frame>from baseline to last value on treatment in between 36 months</time_frame>
        <population>FAS- All patients were considered for the full analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients Treated With Viramune in Combination With Truvada</title>
            <description>Viramune one tablet 200 mg qd for two weeks, then 200 mg bid, Truvada one tablet qd</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Change From Baseline in Total Cholesterol to Last Value on Treatment</title>
          <description>The change in total cholesterol from baseline to the last value in treatment</description>
          <population>FAS- All patients were considered for the full analysis set.</population>
          <units>mg/dl</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="262"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0" lower_limit="-12.0" upper_limit="40.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Summary of Change From Baseline in High-density Lipoprotein (HDL) Cholesterol to Last Value on Treatment</title>
        <description>The change in High-density lipoprotein (HDL) cholesterol from baseline to the last value in treatment</description>
        <time_frame>from baseline to last value on treatment in between 36 months</time_frame>
        <population>FAS- All patients were considered for the full analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients Treated With Viramune in Combination With Truvada</title>
            <description>Viramune one tablet 200 mg qd for two weeks, then 200 mg bid, Truvada one tablet qd</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Change From Baseline in High-density Lipoprotein (HDL) Cholesterol to Last Value on Treatment</title>
          <description>The change in High-density lipoprotein (HDL) cholesterol from baseline to the last value in treatment</description>
          <population>FAS- All patients were considered for the full analysis set.</population>
          <units>mg/dl</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" lower_limit="-1.0" upper_limit="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Summary of Change From Baseline in Low-density Lipoprotein (LDL) Cholesterol to Last Value on Treatment</title>
        <description>The change in Low-density lipoprotein (LDL) cholesterol from baseline to the last value in treatment</description>
        <time_frame>from baseline to last value on treatment in between 36 months</time_frame>
        <population>FAS- All patients were considered for the full analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients Treated With Viramune in Combination With Truvada</title>
            <description>Viramune one tablet 200 mg qd for two weeks, then 200 mg bid, Truvada one tablet qd</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Change From Baseline in Low-density Lipoprotein (LDL) Cholesterol to Last Value on Treatment</title>
          <description>The change in Low-density lipoprotein (LDL) cholesterol from baseline to the last value in treatment</description>
          <population>FAS- All patients were considered for the full analysis set.</population>
          <units>mg/dl</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="208"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="-15.0" upper_limit="27.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Summary of Change From Baseline in Triglycerides to Last Value on Treatment</title>
        <description>The change in triglycerides from baseline to the last value in treatment</description>
        <time_frame>from baseline to last value on treatment in between 36 months</time_frame>
        <population>FAS- All patients were considered for the full analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients Treated With Viramune in Combination With Truvada</title>
            <description>Viramune one tablet 200 mg qd for two weeks, then 200 mg bid, Truvada one tablet qd</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Change From Baseline in Triglycerides to Last Value on Treatment</title>
          <description>The change in triglycerides from baseline to the last value in treatment</description>
          <population>FAS- All patients were considered for the full analysis set.</population>
          <units>mg/dl</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="267"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.0" lower_limit="-54.0" upper_limit="29.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Summary of Change From Baseline in Glucose to Last Value on Treatment</title>
        <description>The change in Glucose from baseline to the last value in treatment</description>
        <time_frame>from baseline to last value on treatment in between 36 months</time_frame>
        <population>FAS- All patients were considered for the full analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients Treated With Viramune in Combination With Truvada</title>
            <description>Viramune one tablet 200 mg qd for two weeks, then 200 mg bid, Truvada one tablet qd</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Change From Baseline in Glucose to Last Value on Treatment</title>
          <description>The change in Glucose from baseline to the last value in treatment</description>
          <population>FAS- All patients were considered for the full analysis set.</population>
          <units>mg/dl</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="276"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-8.0" upper_limit="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Log10 Change From Baseline in Viral Load to Last Value on Treatment</title>
        <description>For calculation of this measure switch patients are included in the total which had no viral load decrease.</description>
        <time_frame>from baseline to last value on treatment in between 36 months</time_frame>
        <population>FAS- All patients were considered for the full analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients Treated With Viramune in Combination With Truvada</title>
            <description>Viramune one tablet 200 mg qd for two weeks, then 200 mg bid, Truvada one tablet qd</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Log10 Change From Baseline in Viral Load to Last Value on Treatment</title>
          <description>For calculation of this measure switch patients are included in the total which had no viral load decrease.</description>
          <population>FAS- All patients were considered for the full analysis set.</population>
          <units>(log10 copies) / ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" lower_limit="-4.53" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Change From Baseline in CD4+ Count to Last Value on Treatment</title>
        <time_frame>from baseline to last value on treatment in between 36 months</time_frame>
        <population>FAS- All patients were considered for the full analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients Treated With Viramune in Combination With Truvada</title>
            <description>Viramune one tablet 200 mg qd for two weeks, then 200 mg bid, Truvada one tablet qd</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Change From Baseline in CD4+ Count to Last Value on Treatment</title>
          <population>FAS- All patients were considered for the full analysis set.</population>
          <units>(cells) / mm^3</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141" lower_limit="30.5" upper_limit="276.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Non-serious Drug-related AEs as Judged by the Investigator</title>
        <description>Total number of patients with investigator defined non-serious drug-related AEs was reported.</description>
        <time_frame>from baseline to last value on treatment in between 36 months</time_frame>
        <population>FAS- All patients were considered for the full analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients Treated With Viramune in Combination With Truvada</title>
            <description>Viramune one tablet 200 mg qd for two weeks, then 200 mg bid, Truvada one tablet qd</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Non-serious Drug-related AEs as Judged by the Investigator</title>
          <description>Total number of patients with investigator defined non-serious drug-related AEs was reported.</description>
          <population>FAS- All patients were considered for the full analysis set.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="334"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Investigator's Global Clinical Assessment of Patient General Health Status</title>
        <description>Investigators opinion of patients general health condition at baseline versus last evaluation on treatment</description>
        <time_frame>from baseline to last value on treatment in between 36 months</time_frame>
        <population>FAS- All patients were considered for the full analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Evaluation Assessment at Baseline</title>
            <description>Patients treated with Viramune in combination with Truvada (Investigators opinion of patients general health condition at baseline)</description>
          </group>
          <group group_id="O2">
            <title>Last Evaluation Assessment on Treatment</title>
            <description>Patients treated with Viramune in combination with Truvada (Investigators opinion of patients general health condition at last evaluation on treatment within 36 months)</description>
          </group>
        </group_list>
        <measure>
          <title>Investigator's Global Clinical Assessment of Patient General Health Status</title>
          <description>Investigators opinion of patients general health condition at baseline versus last evaluation on treatment</description>
          <population>FAS- All patients were considered for the full analysis set.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="334"/>
                <count group_id="O2" value="334"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="193"/>
                    <measurement group_id="O2" value="273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bad</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>36 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Patients Treated With Viramune in Combination With Truvada</title>
          <description>Viramune one tablet 200 mg OD for two weeks, then 200 mg BID, Truvada one tablet QD</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anogenital dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Rectal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Condition aggravated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Disease recurrence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Hepatitis toxic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anogenital warts</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Pilonidal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Face injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Oligodendroglioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebellar ataxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Nervous system disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Neuromyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Nystagmus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Post herpetic neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Drug abuse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Debridement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

